ECONOMIC BENEFIT OF FARICIMAB COMPARED TO AFLIBERCEPT 8MG IN TREATING PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION OR DIABETIC MACULAR EDEMA IN THE UNITED STATES

被引：0
|
作者：
Tabano, D. [1 ]
El Moustaid, F. [1 ]
Rosettie, K. L. [1 ]
Ko, S. [1 ]
Meer, E. [2 ]
Brodie, F. L. [2 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE25
引用
收藏
页码：S61 / S61
页数：1
相关论文
共 50 条
  • [1] Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
    Liberski, Slawomir
    Wichrowska, Malgorzata
    Kociecki, Jaroslaw
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [2] Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
    Desideri, Lorenzo Ferro
    Traverso, Carlo Enrico
    Nicolo, Massimo
    Munk, Marion R.
    [J]. PHARMACEUTICS, 2023, 15 (05)
  • [3] RELATIVE EFFECTIVENESS OF FARICIMAB VS AFLIBERCEPT 8 MG AFTER LOADING PHASE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA
    Buhrer, C.
    Tabano, D.
    Cox, O.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S47 - S47
  • [4] Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1646): : 45 - 46
  • [5] BUDGET IMPACT ANALYSIS OF FARICIMAB FOR TREATING PATIENTS WITH DIABETES MACULAR EDEMA OR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN PANAMA
    Hidalgo, J.
    Ordonez, J.
    Avlia, P.
    Munoz, J. M.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S93 - S93
  • [6] BUDGET IMPACT ANALYSIS OF FARICIMAB FOR TREATING PATIENTS WITH DIABETES MACULAR EDEMA OR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN GUATEMALA
    Hidalgo, J.
    Ordonez, J.
    Deutschmann, B.
    Arriola, A.
    Del Cid, J. M.
    Bustamante, W. Makepeace
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S159 - S159
  • [7] ECONOMIC BURDEN OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA IN COLOMBIA
    Robles, A.
    Gil Rojas, Y.
    Amaya, D.
    Sardi Correa, C.
    Hernandez, F.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S71 - S72
  • [8] Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
    Quah, Nicole Q. X.
    Javed, Khawaja Muhammad Ammar Ali
    Arbi, Lamees
    Hanumunthadu, Daren
    [J]. CLINICAL OPHTHALMOLOGY, 2024, 18 : 1479 - 1490
  • [9] ENVIRONMENTAL IMPACT OF AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA IN THE NETHERLANDS
    Quist, S.
    Paulissen, J.
    Freriks, R. D.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S317 - S318
  • [10] BUDGET IMPACT ANALYSIS OF FARICIMAB FOR TREATING PATIENTS WITH DIABETES MACULAR EDEMA OR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN COSTA RICA
    Hidalgo, J.
    Ordonez, J.
    Salas, M.
    Wu, L.
    Acevedo, R.
    Gutierrez, J. C.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S136 - S136
12345